Abstract：
The prevalence of non-alcoholic fatty pancreas disease (NAFPD) is estimated as 2-46% among patients without known pancreatic diseases. An association between NAFPD and non-alcoholic fatty liver disease (NAFLD) has been proposed, as well as an association between NAFPD and pancreatic exocrine insufficiency (PEI).
Patients with histologically confirmed NAFLD were included in the study. The control group consisted of individuals included in a surveillance screening program. Magnetic resonance imaging (MRI) of the pancreas was performed in all patients and fat measurement was made using 2-point Dixon imaging. Fecal elastase-1 (FE-1) was performed to evaluate pancreatic exocrine function. Additionally, a 13C-mixed triglyceride breath test (13 C-MTG-BT) was performed in patients with FE-1 < 200 μg/g.
Imaging signs of NAFPD were present in 17 (71%) patients; 11 (85%) from the NAFLD group and 6 (55%) from the control group. FE-1 < 200 μg/g was found in six (25%) patients (four in the NAFLD group and two in the control group); however, none of them had clinical symptoms of PEI. Therefore, in five out of six patients with low FE-1, a 13C-MTG-BT was performed, showing normal results (>20.9%) in all tested patients. Furthermore, the serum nutritional panel was normal in all patients with low FE-1. A systematic review identified five studies relevant to the topic.
NAFPD was found in 85% of patients with NAFLD and in 55% of control patients. We did not diagnose PEI in either group. A literature review showed PEI in 9-56% of patients with NAFPD.
Patients with histologically confirmed NAFLD were included in the study. The control group consisted of individuals included in a surveillance screening program. Magnetic resonance imaging (MRI) of the pancreas was performed in all patients and fat measurement was made using 2-point Dixon imaging. Fecal elastase-1 (FE-1) was performed to evaluate pancreatic exocrine function. Additionally, a 13C-mixed triglyceride breath test (13 C-MTG-BT) was performed in patients with FE-1 < 200 μg/g.
Imaging signs of NAFPD were present in 17 (71%) patients; 11 (85%) from the NAFLD group and 6 (55%) from the control group. FE-1 < 200 μg/g was found in six (25%) patients (four in the NAFLD group and two in the control group); however, none of them had clinical symptoms of PEI. Therefore, in five out of six patients with low FE-1, a 13C-MTG-BT was performed, showing normal results (>20.9%) in all tested patients. Furthermore, the serum nutritional panel was normal in all patients with low FE-1. A systematic review identified five studies relevant to the topic.
NAFPD was found in 85% of patients with NAFLD and in 55% of control patients. We did not diagnose PEI in either group. A literature review showed PEI in 9-56% of patients with NAFPD.
摘要：
■在没有已知胰腺疾病的患者中，非酒精性脂肪胰腺疾病（NAFPD）的患病率估计为2-46％。NAFPD和非酒精性脂肪性肝病（NAFLD）之间的关联已被提出，以及NAFPD与胰腺外分泌功能不全（PEI）之间的关联。
■将组织学证实的NAFLD患者纳入研究。对照组由纳入监测筛查计划的个体组成。对所有患者进行胰腺的磁共振成像（MRI），并使用2点Dixon成像进行脂肪测量。使用粪便弹性蛋白酶-1（FE-1）评估胰腺外分泌功能。此外,对FE-1<200μg/g的患者进行13C混合甘油三酯呼气试验(13C-MTG-BT)。
■NAFPD的影像学征象出现在17例（71%）患者中；NAFLD组11例（85%），对照组6例（55%）。FE-1<200μg/g见于6例(25%)患者(NAFLD组4例,对照组2例);然而,均无PEI临床症状。因此,在6例FE-1低的患者中，有5例进行了13C-MTG-BT，在所有测试患者中显示正常结果(>20.9%)。此外，所有低FE-1患者的血清营养组正常。系统综述确定了与该主题相关的五项研究。
■在85%的NAFLD患者和55%的对照患者中发现了NAFPD。两组均未诊断PEI。文献综述显示9-56%的NAFPD患者发生PEI。
■将组织学证实的NAFLD患者纳入研究。对照组由纳入监测筛查计划的个体组成。对所有患者进行胰腺的磁共振成像（MRI），并使用2点Dixon成像进行脂肪测量。使用粪便弹性蛋白酶-1（FE-1）评估胰腺外分泌功能。此外,对FE-1<200μg/g的患者进行13C混合甘油三酯呼气试验(13C-MTG-BT)。
■NAFPD的影像学征象出现在17例（71%）患者中；NAFLD组11例（85%），对照组6例（55%）。FE-1<200μg/g见于6例(25%)患者(NAFLD组4例,对照组2例);然而,均无PEI临床症状。因此,在6例FE-1低的患者中，有5例进行了13C-MTG-BT，在所有测试患者中显示正常结果(>20.9%)。此外，所有低FE-1患者的血清营养组正常。系统综述确定了与该主题相关的五项研究。
■在85%的NAFLD患者和55%的对照患者中发现了NAFPD。两组均未诊断PEI。文献综述显示9-56%的NAFPD患者发生PEI。
